Literature DB >> 6410084

Effects of external radiation therapy for cancer of the prostate on the serum concentrations of testosterone, follicle-stimulating hormone, luteinizing hormone and prolactin.

R Tomić, B Bergman, J E Damber, B Littbrand, P O Löfroth.   

Abstract

Testosterone, luteinizing hormone, follicle-stimulating hormone and prolactin were analyzed in serum from 31 patients with carcinoma of the prostate treated primarily with megavoltage radiation therapy. The total tumor dose varied between 58 and 71 gray (mean 63.5 gray). Absorbed doses to the testes were measured at approximately 1 to more than 10 gray. We investigated retrospectively 17 patients 3 to 60 months (mean 20 months) after therapy and found significantly lower serum testosterone concentrations and significantly higher luteinizing and follicle-stimulating hormone concentrations than in age-matched controls. Of the patients 14 were followed before and after radiation treatment. Testosterone concentrations were reduced significantly 1 week as well as 3 months after treatment but pre-treatment values were found on analysis 6 and 12 months after treatment. The values for luteinizing and follicle-stimulating hormones were significantly higher 3, 6 and 12 months after radiation treatment compared to pre-treatment values. The follicle-stimulating hormone value already increased after 1 week. The greatest observed testosterone alteration occurred 1 week after treatment in patients who received more than 10 gray over the gonads. The use of lead shields protecting the testes reduced the dose absorbed to the gonads by approximately 50 per cent.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6410084     DOI: 10.1016/s0022-5347(17)51110-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists.

Authors:  Howard Huaihan Pai; Tom Pickles; Mira Keyes; Stuart Jones; Rachel E McDonald; Mary Lesperance; Eric Berthelet
Journal:  Can Urol Assoc J       Date:  2011-06       Impact factor: 1.862

2.  Low-dose radiation therapy for testicular intraepithelial neoplasia.

Authors:  K P Dieckmann; A Besserer; V Loy
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer.

Authors:  Eric K Oermann; Simeng Suy; Heather N Hanscom; Joy S Kim; Sue Lei; Xia Yu; Guowei Zhang; Brook Ennis; Joyann P Rohan; Nathaniel Piel; Benjamin A Sherer; Devin Borum; Viola J Chen; Gerald P Batipps; Nicholas L Constantinople; Stephen W Dejter; Gaurav Bandi; John Pahira; Kevin G McGeagh; Lucile Adams-Campbell; Reena Jha; Nancy A Dawson; Brian T Collins; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  J Hematol Oncol       Date:  2011-03-27       Impact factor: 17.388

4.  Long-term effects on sexual function and fertility after treatment of testicular cancer.

Authors:  J T Hartmann; C Albrecht; H J Schmoll; M A Kuczyk; C Kollmannsberger; C Bokemeyer
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

5.  Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression.

Authors:  Whoon Jong Kil; Romaine C Nichols; Bradford S Hoppe; Christopher G Morris; Robert B Marcus; William Mendenhall; Nancy P Mendenhall; Zuofeng Li; Joseph A Costa; Christopher R Williams; Randal H Henderson
Journal:  Acta Oncol       Date:  2013-04       Impact factor: 4.089

6.  Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408.

Authors:  R Charles Nichols; Chen Hu; Jean-Paul Bahary; Kenneth L Zeitzer; Luis Souhami; Mark H Leibenhaut; Marvin Rotman; Elizabeth M Gore; Alexander G Balogh; David McGowan; Jeff Michalski; Adam Raben; Shari Rudoler; Christopher U Jones; Howard Sandler
Journal:  Adv Radiat Oncol       Date:  2017-08-03

7.  Impact and Outcomes of Pretreatment Total Serum Testosterone on Localized Prostate Cancer Patients.

Authors:  Brittni M Usera; Polly Creveling; Jonathan D Tward
Journal:  Prostate Cancer       Date:  2020-01-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.